Diaceutics Past Earnings Performance
Past criteria checks 1/6
Diaceutics's earnings have been declining at an average annual rate of -17.7%, while the Life Sciences industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 17.8% per year. Diaceutics's return on equity is 0.01%, and it has net margins of 0.03%.
Key information
-17.7%
Earnings growth rate
-24.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 17.8% |
| Return on equity | 0.01% |
| Net Margin | 0.03% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Diaceutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 22 | 0 | 20 | 0 |
| 31 Mar 23 | 21 | 0 | 18 | 0 |
| 31 Dec 22 | 20 | 1 | 16 | 0 |
| 30 Sep 22 | 18 | 0 | 16 | 0 |
| 30 Jun 22 | 16 | 0 | 14 | 0 |
| 31 Mar 22 | 15 | 0 | 13 | 0 |
| 31 Dec 21 | 14 | 1 | 12 | 0 |
| 30 Sep 21 | 14 | 0 | 12 | 0 |
| 30 Jun 21 | 13 | -1 | 11 | 0 |
| 31 Mar 21 | 13 | 0 | 11 | 0 |
| 31 Dec 20 | 13 | 0 | 10 | 0 |
| 30 Sep 20 | 14 | 2 | 9 | 0 |
| 30 Jun 20 | 14 | 3 | 9 | 0 |
| 31 Mar 20 | 14 | 2 | 9 | 0 |
| 31 Dec 19 | 13 | 0 | 8 | 0 |
| 30 Sep 19 | 12 | 0 | 7 | 0 |
| 30 Jun 19 | 11 | 0 | 6 | 0 |
| 31 Mar 19 | 11 | 0 | 6 | 0 |
| 31 Dec 18 | 10 | 1 | 6 | 0 |
| 31 Dec 17 | 7 | 1 | 4 | 0 |
| 31 Dec 16 | 5 | 1 | 2 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
Quality Earnings: DIUX.F has high quality earnings.
Growing Profit Margin: DIUX.F's current net profit margins (0.03%) are lower than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DIUX.F's earnings have declined by 17.7% per year over the past 5 years.
Accelerating Growth: DIUX.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DIUX.F had negative earnings growth (-95.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-11.4%).
Return on Equity
High ROE: DIUX.F's Return on Equity (0.01%) is considered low.